TY - CHAP M1 - Book, Section TI - HIV Lipodystrophy/Facial Lipoatrophy A1 - Tannous, Zeina A1 - Avram, Mathew M. A1 - Tsao, Sandy A1 - Avram, Marc R. PY - 2011 T2 - Color Atlas of Cosmetic Dermatology, 2e AB - HIV lipodystrophy describes a constellation of changes in subcutaneous and visceral fat distribution in patients on antiretroviral therapy. In distinction to “lipoatrophy” (which describes local fat loss), lipodystrophy refers to both the accumulation of fat as well as the loss of fat in other areas. In HIV lipostrophy, the findings include subcutaneous fat loss in the malar and buccal fat pads, ie, facial lipoatrophy, as well as on the extremities. It also features fat accumulation on the dorsocervical fat pad, (Fig 59.1) ie, buffalo hump, breasts, and intra-abdominal cavity. Its characteristic appearance is significant, in that it reduces patient compliance with antiretroviral therapy and deprives patients of HIV status privacy, particularly in communities where HIV rates are high. This disorder is also associated with a host of metabolic disorders with long-term impact on health including hyperglycemia, hyperlipidemia, and hypertriglyceridemia. Treatments vary according to the clinical findings. SN - PB - The McGraw-Hill Companies, Inc. CY - New York, NY Y2 - 2024/03/29 UR - dermatology.mhmedical.com/content.aspx?aid=1175823702 ER -